Autoimmune Thrombocytopenic Purpura
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Autoimmune Thrombocytopenic Purpura is a moderately active landscape with 36 programs across 27 companies. The most active players are Johnson & Johnson, Jiangsu Simcere Pharmaceutical Co., Ltd., Gynecologic Oncology Group. 23 therapies are approved with 5 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
83%
Small molecule
30 of 36 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 36 classified programs, each share of the total. Modality classified for 100% of 36 pipeline programs.
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)